Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma ? a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study)-Reference-Cited by-同舟云学术

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma ? a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study)

Published:1992 Issue:S1 Volume:31 Page:S1-S6
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother. Pharmacol.

Author:

Kawai Saburo,Okamura Jun,Ogawa Makoto,Ohashi Yasuo,Tani Masayoshi,Inoue Jushiro,Kawarada Yoshifumi,Kusano Mitsuo,Kubo Yasuhiko,Kuroda Chikazumi,Sakata Yu,Shimamura Yoshiyuki,Jinno Kenji,Takahashi Akira,Takayasu Kenichi,Tamura Kazuo,Nagasue Naofumi,Nakanishi Yoshimi,Makino Masaoki,Masuzawa Manabu,Mikuriya Shuichi,Monden Morito,Yumoto Yasuhiro,Mori Takesada,Oda Toshitsugu,

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF00687096.pdf

Reference16 articles.

1. Hirai K, Kawazoe Y, Yamashita K, Aoki Y, Fujimoto T, Sakai T, Majima Y, Abe M, Tanikawa K (1989) Arterial chemotherapy and transcatheter arterial embolization therapy for non-resectable hepatocellular carcinoma. Cancer Chemother Pharmacol 23 (Suppl):S37

2. Kanematsu T, Furuta T, Takenaka K, Matsumata T, Yoshida Y, Nishizaki T, Hasuo K, Sugimachi K (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10:98

3. Kawai S, Okamura J, Ogawa M, Inoue, J, Ohashi Y, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Tani M, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Mikuriya S, Monden M, Yumoto Y, Mori T, Oda T (1992) An assessment of criteria for evaluating efficacy of L-TAE for the treatment of HCC (in Japanese). Acta Hepatol Jpn 33:86

4. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T, Yokoyama I (1983) Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 19:1053

5. Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

2. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails;BMC Gastroenterology;2024-06-07

3. Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment;Frontiers in Oncology;2023-06-20

4. Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis;Cancers;2023-06-13

5. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada;Cancer Treatment Reviews;2023-04